You searched for partnering

- 22 Octobre 2025

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImChec...

- 22 Décembre 2025

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC1...

- 18 Mai 2026

Ipsen initiates a new share buy-back program

Ipsen initiates a new share buy-back program...

- 01 Avril 2026

Ipsen announces the availability of its 2025 Universal Registration Document

Ipsen announces the availability of its 2025 Universal Registration Document...

- 07 Juillet 2026

Ipsen – Half year statement – 2026 06 30

Half-year statement of the liquidity agreement between IPSEN SA and NATIXIS ODDO BHF...

- 15 Décembre 2025

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ...

- 13 Mai 2026

Ipsen S.A. – Evolution of the composition of the Board of Directors

Ipsen S.A. – Evolution of the composition of the Board of Directors...

- 09 Mars 2026

Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the on...